Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?

J Thorac Oncol. 2023 Mar;18(3):e30-e31. doi: 10.1016/j.jtho.2023.01.004.

Authors

Sai-Hong Ignatius Ou¹, Edward S Kim²

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address: [email protected].
² City of Hope Orange County, City of Hope National Medical Center, Irvine, California.

PMID: 36842818
DOI: 10.1016/j.jtho.2023.01.004

No abstract available

Publication types

Letter
Comment

MeSH terms

Carbazoles / pharmacology
Carbazoles / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Protein Kinase Inhibitors / therapeutic use
Receptor Protein-Tyrosine Kinases

Substances

ceritinib
alectinib
brigatinib
Carbazoles
Receptor Protein-Tyrosine Kinases
Protein Kinase Inhibitors